口服糖皮质激素与早产风险关联的数据源差异:结果调和
该研究比较加州医疗补助(Medi-Cal)与前瞻性队列MotherToBaby中类风湿关节炎(RA)孕妇早孕口服糖皮质激素(OGC)与早产风险的关联。Medi-Cal中无OGC者早产风险17.3%,调整后RR 1.00(95%CI 0.71,1.42);MotherToBaby中无OGC者早产风险9.7%,调整后RR 1.85(95%CI 1.20,2.84)。Medi-Cal基线早产风险更高且OGC剂量分布更低可能解释差异,需研究自身免疫病严重程度与治疗不足对低收入人群早产风险的影响。
要点
- Medi-Cal中OGC与早产无关联(调整RR 1.00,95%CI 0.71,1.42),MotherToBaby中风险升高1.85倍(95%CI 1.20,2.84)。
- 限制为高中及以下学历者后,Medi-Cal调整RR 1.16(95%CI 0.74,1.80),MotherToBaby调整RR 0.81(95%CI 0.25,2.64)。
- MotherToBaby累积OGC剂量中位数684 mg高于Medi-Cal的300 mg,≤300 mg剂量与早产风险升高无关。
核心结论
- Medi-Cal中较高的基线早产风险和较低的OGC剂量分布可能解释两数据源间OGC与早产关联的差异。
- 需开展研究以理解自身免疫病严重程度和治疗不足对低收入人群早产风险的影响。
研究设计与样本
- 分别利用加州医疗补助(Medi-Cal)2007-2013年数据(n=844)和前瞻性队列MotherToBaby妊娠研究2003-2014年数据(n=528),估计孕140天前OGC暴露与早产风险的RR。
- 探讨两数据源在社会经济状态、OGC剂量分布、暴露错分和RA严重程度混杂方面的差异。
主要发现
- 无OGC暴露者早产风险在Medi-Cal为17.3%,在MotherToBaby为9.7%。
- OGC与早产在Medi-Cal中无关联(调整RR 1.00,95%CI 0.71,1.42),在MotherToBaby中风险升高1.85倍(95%CI 1.20,2.84)。
- 限制为高中及以下学历者后,无OGC暴露者早产风险在Medi-Cal为15.9%,在MotherToBaby为16.7%;调整RR分别为1.16(95%CI 0.74,1.80)和0.81(95%CI 0.25,2.64)。
- MotherToBaby累积OGC剂量中位数684 mg高于Medi-Cal的300 mg;OGC剂量≤300 mg与早产风险升高无关。
- 暴露错分和RA严重程度混杂不太可能解释两数据源间的差异。
局限性
- 需开展研究以理解自身免疫病严重程度和治疗不足对低收入人群早产风险的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate causes of discrepancies in the association between early pregnancy oral glucocorticoid (OGC) use and preterm birth risk among women with rheumatoid arthritis (RA) in health care utilization data from California Medicaid (Medi-Cal) and the prospective cohort MotherToBaby Pregnancy Studies. METHODS: Separately, we estimated risk ratios (RRs) between OGC exposure before gestational day 140 and preterm birth risk in data from Medi-Cal (2007-2013; n = 844) and MotherToBaby (2003-2014; n = 528). We explored differences in socioeconomic status, OGC dose distribution, exposure misclassification, and confounding by RA severity across the data sources. RESULTS: Preterm birth risk in women without OGC was 17.3% in Medi-Cal and was 9.7% in MotherToBaby. There was no association between OGC and preterm birth in Medi-Cal (adjusted RR 1.00 [95% confidence interval (95% CI) 0.71, 1.42]), and a 1.85-fold (95% CI 1.20, 2.84) increased preterm birth risk in MotherToBaby. When restricting each sample to women with a high-school diploma or less, preterm birth risk following no OGC exposure was 15.9% in Medi-Cal and 16.7% in MotherToBaby; adjusted RRs were 1.16 (95% CI 0.74, 1.80) in Medi-Cal and 0.81 (95% CI 0.25, 2.64) in MotherToBaby. Cumulative OGC dose was higher in MotherToBaby (median 684 mg) than in Medi-Cal (median 300 mg). An OGC dose of ≤300 mg was not associated with increased preterm birth risk. Exposure misclassification and confounding by RA severity were unlikely explanations of differences. CONCLUSION: Higher baseline preterm birth risk and lower OGC dose distribution in Medi-Cal may explain the discrepancies. Studies are needed to understand the effects of autoimmune disease severity and undertreatment on preterm birth risk in low-income populations.
引用
- Palmsten K, Bandoli G, Vazquez-Benitez G, et al. Differences in the Association Between Oral Glucocorticoids and Risk of Preterm Birth by Data Source: Reconciling the Results. Arthritis Care Res (Hoboken). 2022. PMID: 35089649. doi:10.1002/acr.24865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。